The shadow of generic rivalry has consistently loomed over copyright’s famous drug, Viagra, sparking questions about the outlook of connected pharmaceutical investments. While early times saw substantial profits, the intellectual property lapse has allowed the way for cheaper copies, likely reducing revenue and creating a significant risk for sha